Treatment options for the patient who does not respond well to initial antidepressant therapy

Journal of Psychiatric Practice

Volumn 15, Issue 3, 2009, Pages 202-210

  Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Aripiprazole; Augmentation; Buspirone; Combination treatment; D; Dopamine agonists; Electroconvulsive therapy; Lithium; Pindolol; Psychostimulants; Star; Thyroid supplementation; Treatment resistant depression (TRD); Vagus nerve stimulation

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; DESVENLAFAXINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PINDOLOL; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANXIETY; ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NERVOUSNESS; PATIENT SATISFACTION; PROPHYLAXIS; PSYCHOSIS; REMISSION; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PIPERAZINES; PSYCHOTROPIC DRUGS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VAGUS NERVE STIMULATION;

EID: 67650348265     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000351880.30013.2a     Document Type: Review

References (38)

1. Preskorn SH. Results of the STARz.ast;D study: Implications for clinicians and drug developers. J Psychiatr Pract 2009;15:45-9.
2. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
3. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARz.ast;D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
4. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42.
6. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STARz.ast;D report. Am J Psychiatry 2006;163:1161-72.
7. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STARz.ast;D report. Am J Psychiatry 2006;163:1519-30.
8. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STARz.ast;D report. Am J Psychiatry 2006;163:1531-41.
9. Warden D, Rush AJ, Trivedi MH, et al. STARz.ast;D Project results: A comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59.
10. Preskorn SH. The appearance of knowledge. Journal of Practical Psychiatry and Behavioral Health 1997;3:233-8 (updated revision in press J Psychiatr Pract 2009;15:4).
11. Trivedi M, Bettinger T, Kleiber B. Treatment-refractory depression. In: Preskorn SH, Feighner JP, Stanga CY, et al. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag; 2004:447-88.
12. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of anti-depressant resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-9.
13. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antide-pressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343-396.
14. Qaseem A, Snow V, Denberg TD, et al, Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-33.
15. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo controlled study. J Clin Psychiatry 2007;68: 843-53.
16. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo controlled study. J Clin Psychophar-macol 2008;28:156-65.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-9.
18. Sheehan DH. The anxiety disease. New York: Scribners; 1983.
19. Abilify (aripiprazole) package insert. section 14.3, Bristol-Myers Squibb/Otsuka Pharmaceuticals, August, 2008 (available at www.abilify.com/pdf/ pi.aspx, accessed May 2, 2009).
20. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983;40:1335-42.
21. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363-6.
22. Rouillon F, Gorwood P. The use of lithium to augment anti-depressant medication. J Clin Psychiatry 1998;59(suppl 5):32-41.
23. Stein G, Bernadt M. Lithium augmentation therapy in tri-cyclic resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162: 634-40.
24. Esposito S, Prange AJ, Jr, Golden RN. The thyroid axis and mood disorders: Overview and future prospects. Psycho-pharmacol Bull.1997;33:205-217.
25. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
26. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy, 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006.
27. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial respon-ders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-45.
28. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STARz.ast;D report. Am J Psychiatry 2008;165: 342-51.
29. Fava M, Rush AJ, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: A replication and extension. Can J Psychiatry. 2006;51: 823-35.
30. Blier P, Bergeron R. The use of pindolol to potentiate anti-depressant medication. J Clin Psychiatry 1998;59(suppl 5):16-25.
31. Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997;58:437-9.
32. Preskorn SH, Drevets WC. Neuroscience basis of clinical depression: Implications for future antidepressant drug development. J Psychiatr Pract 2009;15:125-32.
33. Andrée B, Thorberg SO, Halldin C, et al. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl) 1999;144:303-5.
34. Nelson JC, Mazure CM, Bowers MB, Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-7.
35. Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1991;3:209-13.
36. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms. Neuropsychopharma-cology 2006;31:1345-55.
37. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial. Biol Psychiatry 2005;58: 347-54.
38. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment resistant depression. Biol Psychiatry 2005;58:364-73.